Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.…
Ethics submission for Ox-1 Phase 1 study
Theracryf (LON: TCF) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 9 employees.
The shares were at 0.1650 GBp on 20 November 2026, down 13.2% over 52 weeks. Its 52-week range is 0.1600 GBp to 0.2680 GBp: the price is 38.4% below the high and 3.1% above the low.
Its market capitalisation is 3.55M GBP.
Theracryf reports return on equity of -130.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.53M GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.